BROSSARD, January 20, 2025 – Mantra Pharma, a leading Quebec-based developer and marketer of generic medications, announces the upcoming launch of M-METFORMIN, an addition to its generic range.

A new option in the metformin market

Starting January 2025, Mantra Pharma will offer a new strength in the metformin market with M-METFORMIN 1000 mg. M-Metformin will also be available in 500 mg and 850 mg tablets, therefore offering a complete range. This will allow healthcare professionals to more precisely adjust treatments according to each patient’s specific needs. The three strengths are available in bottles of 500 tablets.

Mantra Pharma continues to support the healthcare needs of Quebecers with the launch of this new range.

Please consult your healthcare professional before making any healthcare decisions or for guidance about a specific medical condition.

Availability and Accessibility

M-METFORMIN will be available in Quebec pharmacies through major pharmaceutical wholesalers. Mantra Pharma confirms that the product will be listed on the RAMQ formulary from February 5, 2025, for maximum accessibility.

About Mantra Pharma

Founded in Quebec, Mantra Pharma is passionate about improving access to essential treatments as well as supporting pharmacies and healthcare professionals to provide great service. Mantra Pharma offers generic medications, natural health products and over-the-counter pharmaceutical products, and also markets its own brands (mcal, Denta, Eczederm, and Urederma) in pharmacies across Canada. With facilities in Brossard and Lévis, the company actively contributes to improving healthcare in Quebec and Canada.

For more information:

Dominic Martel
Marketing Director
dmartel@mantrapharma.ca
450 678 7088 | 514 805 9054